Because high affinity is not per se the most important characteristic for tumor targeting, future research could therefore focus on the development of a bivalent Ac2-Ec4.1 DARPin dimer or other construct that may have even better binding potential for tumor-associated EpCAM. This evidence concerns the gene ADCY2 and neoplasm.